Dynamics of the gut microbiome in subjects challenged with Shigella sonnei 53G in a controlled human infection model

Diarrheal disease is a major contributor to the global disease burden and can lead to an increased individual risk of chronic sequelae post-infection, such as irritable bowel syndrome, reactive arthritis, and altered gut permeability. Understanding the differential responses of individuals to entero...

Full description

Saved in:

Bibliographic Details
Published in	mSphere Vol. 10; no. 4; p. e0090624
Main Authors	Liechty, Zachary, Baldwin, Arianna, Isidean, Sandra, Suvarnapunya, Akamol, Frenck, Robert, Porter, Chad, Goodson, Michael
Format	Journal Article
Language	English
Published	United States American Society for Microbiology 29.04.2025
Subjects	16S rRNA Adult Anti-Bacterial Agents - therapeutic use Bacteria - classification Bacteria - genetics Bacteria - isolation & purification controlled human infection model diarrhea Dysentery, Bacillary - drug therapy Dysentery, Bacillary - microbiology fecal microbiome Feces - microbiology Female Gastrointestinal Microbiome - drug effects Human Microbiome Humans Male Middle Aged Research Article RNA, Ribosomal, 16S - genetics Shigella Shigella sonnei - genetics Young Adult 16S rRNA diarrhea controlled human infection model Shigella fecal microbiome
Online Access	Get full text
ISSN	2379-5042 2379-5042
DOI	10.1128/msphere.00906-24

Cover

More Information
Summary:	Diarrheal disease is a major contributor to the global disease burden and can lead to an increased individual risk of chronic sequelae post-infection, such as irritable bowel syndrome, reactive arthritis, and altered gut permeability. Understanding the differential responses of individuals to enteropathogen exposure can elucidate factors that could lead to treatments or preventative measures to reduce the disease burden. Here, we use a controlled human infection model study to directly identify the effects of Shigella sonnei 53G infection on the microbiome. We identified taxa that were more or less abundant in participants who would develop shigellosis during the study, as well as persistent changes after recovery in the microbiomes of participants who developed severe symptoms. Understanding these changes could elucidate ways to prevent Shigella infection or recover altered microbiomes after recovery. This study is registered with ClinicalTrials.gov as NCT02816346 .
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors declare no conflict of interest.
ISSN:	2379-5042 2379-5042
DOI:	10.1128/msphere.00906-24